Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma.

[1]  J. C. Carranza Rosenzweig,et al.  Adherence to asthma controller medication regimens. , 2005, Respiratory medicine.

[2]  Tami L. Remington,et al.  Long-acting β-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma , 2005, Current opinion in pulmonary medicine.

[3]  M. Beauchesne,et al.  Use of inhaled corticosteroids following discharge from an emergency department for an acute exacerbation of asthma , 2004, Thorax.

[4]  J. Lötvall.  Combination therapy in asthma -fixed or variable dosing in different patients? , 2004, Current medical research and opinion.

[5]  S. Myou,et al.  Additive blockade of beta 2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate. , 2004, The European respiratory journal.

[6]  R. Beasley,et al.  Increasing compliance with inhaled corticosteroids through the use of combination therapy. , 2004, The Journal of allergy and clinical immunology.

[7]  J. C. Carranza Rosenzweig,et al.  Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. , 2004, The Journal of allergy and clinical immunology.

[8]  H. Nelson,et al.  Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. , 2003, The Journal of allergy and clinical immunology.

[9]  Elisa Lee,et al.  Nonparametric Methods for Comparing Survival Distributions , 2003 .

[10]  L. García-Marcos,et al.  Inhaled corticosteroids plus long-acting β2-agonists as a combined therapy in asthma , 2003, Expert opinion on pharmacotherapy.

[11]  L. Lynd,et al.  Clinical Investigations: AsthmaPatterns of Inhaled Asthma Medication Use: A 3-Year Longitudinal Analysis of Prescription Claims Data From British Columbia, Canada , 2002 .

[12]  P. Kuna,et al.  SYMBICORT® TURBUHALER®: A NEW CONCEPT IN ASTHMA MANAGEMENT , 2002, International journal of clinical practice.

[13]  A. Chuchalin,et al.  Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. , 2002, Respiratory medicine.

[14]  M. Roth,et al.  Interaction between glucocorticoids and β2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling , 2002, The Lancet.

[15]  G. Tipoe,et al.  Overexpression of matrix metalloproteinase‐8 and ‐9 in bronchiectatic airways in vivo , 2002, European Respiratory Journal.

[16]  J. Mak,et al.  Glucocorticoids reverse IL‐1β‐induced impairment of β‐adrenoceptor‐mediated relaxation and up‐regulation of G‐protein‐coupled receptor kinases , 2002 .

[17]  A. Luskin,et al.  A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. , 2001, Clinical therapeutics.

[18]  L. Boulet,et al.  What is new since the last (1999) Canadian Asthma Consensus Guidelines? , 2001, Canadian respiratory journal.

[19]  J. Mauskopf,et al.  Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. , 2001, Respiratory medicine.

[20]  H. Nelson,et al.  Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. , 2001, The Journal of allergy and clinical immunology.

[21]  S. Shrewsbury,et al.  Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) , 2000, BMJ : British Medical Journal.

[22]  A. Knox,et al.  Synergistic Inhibition by β2-Agonists and Corticosteroids on Tumor Necrosis Factor- α –Induced Interleukin-8 Release from Cultured Human Airway Smooth-Muscle Cells , 2000 .

[23]  S. Adlis,et al.  Effect of salmeterol on patients' adherence to their prescribed refills for inhaled corticosteroids. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[24]  R. Tamblyn,et al.  The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.

[25]  Elisa T. Lee,et al.  Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.

[26]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[27]  J. Paton,et al.  Measuring compliance with inhaled medication in asthma. , 1992, Archives of disease in childhood.

[28]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[29]  D. Robinson,et al.  Cost Advantages of Combination Asthma Therapy , 2004, Treatments in respiratory medicine.

[30]  L. Boulet,et al.  Adult Asthma Consensus Guidelines update 2003. , 2004, Canadian respiratory journal.

[31]  L. Fabbri,et al.  Improving patient compliance with asthma therapy. , 2000, Respiratory medicine.

[32]  A V Prochazka,et al.  The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.